Vanda Pharmaceuticals Inc. (VNDA:US) rose 5.1 percent to $11.63 and gained 7.4 percent earlier, the most intraday since Oct. 13. The Rockville, Maryland-based drugmaker was rated new “buy” at Jefferies Group Inc., which cited the sale of Vanda’s U.S. and Canadian rights for its schizophrenia drug Fanapt to Novartis AG (NVS:US).